Abstract:
The aim of this paper was to develop potential technetium 99m-labeled diagnostic imaging agents specific for the detection of A
β plaques. Based on previously obtained Aβ plaque-specific biphenyls containing a benzimidazol group,
99Tc
m and Re-benzimidazol derivatives,
99Tc
m(CO)
3+-EPBI and Re(CO)
3Cl(EPBI), were prepared. The latter showed binding affinities towards A
β(1~40) aggregates in
vitro (
Kd=13.3 μmol/L) by fluorophotometry. 2-(1-Ethylbenzimidazol-2-yl)pyridine(EPBI) and Re(CO)
3Cl(EPBI) were synthesized. Binding affinity of Re(CO)
3Cl(EPBI) for A
β(1~40) aggregates was determined.
99Tc
m(CO)
3+-EPBI was prepared and analyzed by HPLC and paper eletrophoresis. Its biodistribution in mice was obtained. The
Kd value of Re(CO)
3Cl(EPBI) is 13.3 μmol/L. Biodistribution of
99Tc
m(CO)
3+-EPBI in mice shows brain penetration (0.63±0.17) %ID/g (n=3) at 2 min after iv injection in mice and rapid washout from normal brains (0.27±0.03) %ID/g (n=3) at 120 min. It may provide a new strategy to design the early diagnosis radiopharmaceuticals of AD labeled by
99Tc
m(CO)
3+ core according to the result.